$6.30
1.10% yesterday
Nasdaq, Jun 30, 10:16 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Stock price

$6.30
-1.04 14.17% 1M
-1.63 20.55% 6M
-1.74 21.64% YTD
-6.43 50.51% 1Y
-45.13 87.75% 3Y
-77.05 92.44% 5Y
-216.50 97.17% 10Y
-20.10 76.14% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
-0.07 1.10%
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$517.6m
Net debt
positive
Cash
$731.5m
Shares outstanding
162.0m
Valuation (TTM | estimate)
P/E
2.34 | 2.40
P/S
0.81 | 0.95
EV/Sales
0.41 | 0.48
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-40.00%
Return on Equity
30.05%
ROCE
48.55%
ROIC
149.58%
Debt/Equity
-3.02
Financials (TTM | estimate)
Revenue
$1.3b | $1.1b
EBITDA
$467.5m | $488.7m
EBIT
$422.8m
Net Income
$478.7m | $425.9m
Free Cash Flow
$-196.6m
Growth (TTM | estimate)
Revenue
25.92% | 56.85%
EBITDA
240.09% | 366.42%
EBIT
211.83%
Net Income
220.05% | 327.14%
Free Cash Flow
61.66%
Margin (TTM | estimate)
Gross
87.52%
EBITDA
37.25% | 45.67%
EBIT
33.69%
Net
38.14% | 39.80%
Free Cash Flow
-15.67%
More
EPS
$2.69
FCF per Share
$-1.21
Short interest
27.56%
Employees
952.00
Rev per Employee
$720.00k
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Novavax, Inc. forecast:

9x Buy
69%
3x Hold
23%
1x Sell
8%

Analyst Opinions

13 Analysts have issued a Novavax, Inc. forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,255 1,255
26% 26%
100%
- Direct Costs 157 157
57% 57%
12%
1,098 1,098
75% 75%
88%
- Selling and Administrative Expenses 289 289
32% 32%
23%
- Research and Development Expense 387 387
33% 33%
31%
468 468
240% 240%
37%
- Depreciation and Amortization 45 45
1% 1%
4%
EBIT (Operating Income) EBIT 423 423
212% 212%
34%
Net Profit 479 479
220% 220%
38%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
Seeking Alpha
19 days ago
Novavax, Inc. (NASDAQ:NVAX ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Ruxandra Draghia-Akli - EVP and Head of Research & Development John Charles Jacobs Are we ready to go? Are we live?
Positive
Reuters
20 days ago
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.
Neutral
PRNewsWire
20 days ago
Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novavax continues to pursue partnering opportunities to advance further development of these programs GAITHERSBURG, Md. , June 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced resul...
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today